Overview

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

Status:
RECRUITING
Trial end date:
2031-04-01
Target enrollment:
Participant gender:
Summary
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
Phase:
PHASE2
Details
Lead Sponsor:
Vir Biotechnology, Inc.
Treatments:
bulevirtide